Annual Cash & Cash Equivalents
$23.63 M
-$13.03 M-35.54%
December 31, 2022
Summary
- As of March 9, 2025, SRNE annual cash & cash equivalents is $23.63 million, with the most recent change of -$13.03 million (-35.54%) on December 31, 2022.
- During the last 3 years, SRNE annual cash & cash equivalents has risen by +$1.11 million (+4.94%).
- SRNE annual cash & cash equivalents is now -85.11% below its all-time high of $158.74 million, reached on December 31, 2018.
Performance
SRNE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$69.75 M
+$32.09 M+85.23%
June 30, 2023
Summary
- As of March 9, 2025, SRNE quarterly cash and cash equivalents is $69.75 million, with the most recent change of +$32.09 million (+85.23%) on June 30, 2023.
- Over the past year, SRNE quarterly cash and cash equivalents has increased by +$32.09 million (+85.23%).
- SRNE quarterly cash and cash equivalents is now -56.06% below its all-time high of $158.74 million, reached on December 31, 2018.
Performance
SRNE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SRNE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -35.5% | +85.2% |
| 3 y3 years | +4.9% | +85.2% |
| 5 y5 years | +15.7% | +85.2% |
SRNE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -35.5% | at low | -37.7% | +195.1% |
| 5 y | 5-year | -58.1% | +4.9% | -37.7% | +218.5% |
| alltime | all time | -85.1% | -100.0% | -56.1% | -100.0% |
Sorrento Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $69.75 M(+85.2%) |
| Mar 2023 | - | $37.66 M(+59.3%) |
| Dec 2022 | $23.63 M(-35.5%) | $23.63 M(-66.6%) |
| Sep 2022 | - | $70.69 M(+0.5%) |
| Jun 2022 | - | $70.34 M(-37.1%) |
| Mar 2022 | - | $111.91 M(+205.2%) |
| Dec 2021 | $36.66 M(-35.1%) | $36.66 M(-7.7%) |
| Sep 2021 | - | $39.73 M(-48.6%) |
| Jun 2021 | - | $77.29 M(+85.4%) |
| Mar 2021 | - | $41.68 M(-26.2%) |
| Dec 2020 | $56.46 M(+150.7%) | $56.46 M(-24.9%) |
| Sep 2020 | - | $75.18 M(+208.2%) |
| Jun 2020 | - | $24.39 M(+11.4%) |
| Mar 2020 | - | $21.90 M(-2.8%) |
| Dec 2019 | $22.52 M(-85.8%) | $22.52 M(-35.0%) |
| Sep 2019 | - | $34.65 M(-43.6%) |
| Jun 2019 | - | $61.38 M(-32.5%) |
| Mar 2019 | - | $90.97 M(-42.7%) |
| Dec 2018 | $158.74 M(+677.0%) | $158.74 M(+17.2%) |
| Sep 2018 | - | $135.44 M(+189.5%) |
| Jun 2018 | - | $46.78 M(+92.9%) |
| Mar 2018 | - | $24.25 M(+18.7%) |
| Dec 2017 | $20.43 M(-75.2%) | $20.43 M(-46.7%) |
| Sep 2017 | - | $38.32 M(-28.6%) |
| Jun 2017 | - | $53.68 M(+58.3%) |
| Mar 2017 | - | $33.92 M(-58.8%) |
| Dec 2016 | $82.40 M(+111.1%) | $82.40 M(+23.9%) |
| Sep 2016 | - | $66.48 M(-32.3%) |
| Jun 2016 | - | $98.18 M(+371.7%) |
| Mar 2016 | - | $20.81 M(-46.7%) |
| Dec 2015 | $39.04 M | $39.04 M(-33.9%) |
| Sep 2015 | - | $59.07 M(+14.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $51.70 M(-14.5%) |
| Mar 2015 | - | $60.50 M(-15.9%) |
| Dec 2014 | $71.90 M(+127.1%) | $71.90 M(+62.4%) |
| Sep 2014 | - | $44.27 M(-11.7%) |
| Jun 2014 | - | $50.16 M(+67.5%) |
| Mar 2014 | - | $29.95 M(-5.4%) |
| Dec 2013 | $31.67 M(+522.0%) | $31.67 M(+392.5%) |
| Sep 2013 | - | $6.43 M(+11.7%) |
| Jun 2013 | - | $5.75 M(-40.3%) |
| Mar 2013 | - | $9.64 M(+89.3%) |
| Dec 2012 | $5.09 M(+46.9%) | $5.09 M(-21.0%) |
| Sep 2012 | - | $6.45 M(-15.5%) |
| Jun 2012 | - | $7.63 M(+212.1%) |
| Mar 2012 | - | $2.44 M(-29.5%) |
| Dec 2011 | $3.47 M(-34.3%) | $3.47 M(+52.7%) |
| Sep 2011 | - | $2.27 M(-22.3%) |
| Jun 2011 | - | $2.92 M(-38.0%) |
| Mar 2011 | - | $4.71 M(-10.7%) |
| Dec 2010 | $5.28 M(+53.9%) | $5.28 M(+168.5%) |
| Sep 2010 | - | $1.97 M(-9.8%) |
| Jun 2010 | - | $2.18 M(-18.8%) |
| Mar 2010 | - | $2.68 M(-21.8%) |
| Dec 2009 | $3.43 M(>+9900.0%) | $3.43 M(-13.3%) |
| Sep 2009 | - | $3.95 M(+1255.8%) |
| Jun 2009 | - | $291.70 K(-20.0%) |
| Mar 2009 | - | $364.50 K(>+9900.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2008 | - | $416.70 K(+2336.8%) |
| Mar 2008 | - | $17.10 K(-21.9%) |
| Dec 2007 | $21.90 K | $21.90 K(-27.0%) |
| Sep 2007 | - | $30.00 K(-29.9%) |
| Jun 2007 | - | $42.80 K(-43.3%) |
| Mar 2007 | - | $75.50 K |
FAQ
- What is Sorrento Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual cash & cash equivalents year-on-year change?
- What is Sorrento Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Sorrento Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SRNE is $23.63 M
What is the all time high annual cash & cash equivalents for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual cash & cash equivalents is $158.74 M
What is Sorrento Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SRNE annual cash & cash equivalents has changed by -$13.03 M (-35.54%)
What is Sorrento Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SRNE is $69.75 M
What is the all time high quarterly cash and cash equivalents for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly cash and cash equivalents is $158.74 M
What is Sorrento Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SRNE quarterly cash and cash equivalents has changed by +$32.09 M (+85.23%)